Neuraxpharm buys Buccolam brand from Takeda

14 September 2020

CNS specialist Neuraxpharm has acquired the prescription brand Buccolam (oromucosal midazolam) from Japanese pharma major Takeda (TYO: 4502).

Buccolam is the only buccal midazolam approved across Europe. It is indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures, the most common neurological emergency in children with an incidence of 18 to 23 cases per 100,000 per year. Financial terms of the transaction were not revealed.

"We are committing ourselves unwaveringly to identify and offer new solutions for unmet needs in CNS"The product is offered in pre-filled, ready-to-use non-invasive syringes for easy administration by caregivers, is manufactured entirely in Europe, and is currently commercialized in 18 countries in Europe and Israel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK